Specify Company / Ticker to Get the Summary
Dividend History NBTX
Dividend Analytics NBTX
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Nanobiotix
NBTXNanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France. Address: 60 rue de Wattignies, Paris, France, 75012
Analytics
WallStreet Target Price
7.52 USDP/E ratio
–Dividend Yield
–Financials NBTX
Results | 2019 | Dynamics |